NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS)(DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today that favorable results have been obtained in pre-clinical testing using the Company’s proprietary PLX cells to treat limb ischemia, a potential market of over $1 Billion.